Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gecaxitinib hydrochloride - Suzhou Zelgen Biopharmaceuticals

Next Previous
Drug Profile

Gecaxitinib hydrochloride - Suzhou Zelgen Biopharmaceuticals

Alternative Names: Gecacitinib; Gecacitinib - Suzhou Zelgen Biopharmaceuticals; Gecacitinib hydrochloride; Gecacitinib hydrochloride - Suzhou Zelgen Biopharmaceuticals; Gecaxitinib-hydrochloride; Jakotinib hydrochloride; Jaktinib; Jaktinib dihydrochloride monohydrate; Zepuping

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Zelgen Biopharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Antivirals; Skin disorder therapies; Small molecules
  • Mechanism of Action ACVR1 protein inhibitors; Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; Janus kinase 3 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelofibrosis
  • Preregistration Alopecia areata
  • Phase III Ankylosing spondylitis; Atopic dermatitis
  • Phase II Idiopathic pulmonary fibrosis; Plaque psoriasis; Vitiligo
  • Phase I/II Graft-versus-host disease
  • Discontinued Cancer; COVID-19 pneumonia; Systemic lupus erythematosus

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for phase-I development in Alopecia areata in USA (PO, Tablet)
  • 13 Jan 2026 Launched for Myelofibrosis in China (PO), prior to January 2026 (Suzhou Zelgen Biopharmaceuticals pipeline, March 2026)
  • 01 Oct 2025 Ruijin Hospital plans a phase II trial for Graft versus host disease (Treatment-experienced) (PO) in October 2025 (NCT07197112)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top